Top Page
InnoCare Pharma Ltd.
(9969)
InnoCare Pharma Ltd. (9969) vs. iShares MSCI Hong Kong ETF (EWH)
InnoCare Pharma Ltd. Business Overview & Revenue Model
InnoCare Pharma Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.01B | 738.54M | 625.40M | 1.04B | 1.36M |
| Gross Profit | 871.01M | 610.10M | 482.01M | 977.37M | 1.36M |
| EBITDA | -463.49M | -516.55M | -808.28M | 16.23M | -453.44M |
| Net Income | -440.63M | -631.26M | -871.65M | -66.68M | -463.17M |
Balance Sheet | |||||
| Total Assets | 9.41B | 9.92B | 10.32B | 7.40B | 4.54B |
| Cash, Cash Equivalents and Short-Term Investments | 7.29B | 8.22B | 9.01B | 6.25B | 3.97B |
| Total Debt | 1.27B | 1.35B | 1.25B | 1.27B | 1.17B |
| Total Liabilities | 2.66B | 2.74B | 2.68B | 1.74B | 1.38B |
| Stockholders Equity | 6.73B | 7.15B | 7.60B | 5.60B | 3.10B |
Cash Flow | |||||
| Free Cash Flow | -443.78M | -926.00M | -935.88M | -11.00K | -423.79M |
| Operating Cash Flow | -365.55M | -671.34M | -565.55M | 167.06M | -172.52M |
| Investing Cash Flow | 1.11B | 666.91M | -1.73B | -1.73B | -1.11B |
| Financing Cash Flow | -285.60M | 1.31M | 3.09B | 2.54B | 2.24B |
InnoCare Pharma Ltd. Technical Analysis
InnoCare Pharma Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$34.24B | 38.49 | 31.65% | ― | 4.23% | 47.71% | |
61 Neutral | HK$27.92B | ― | -6.35% | ― | 33.63% | 31.50% | |
54 Neutral | HK$23.82B | ― | -23.03% | ― | 461.36% | -16.43% | |
53 Neutral | HK$14.31B | ― | -55.68% | ― | ― | -4.33% | |
51 Neutral | HK$16.14B | ― | -18.87% | ― | 16.35% | -49.63% | |
50 Neutral | AU$2.58B | 3.39 | -57.47% | 2.93% | 36.73% | 13.67% | |
48 Neutral | HK$27.65B | ― | -253.12% | ― | 330.23% | 59.68% |
InnoCare Pharma Ltd. Corporate Events
InnoCare Pharma Ltd. announced that all proposed resolutions at its Annual General Meeting held on June 20, 2025, were passed by shareholders. The resolutions included approval of financial statements, annual and work reports, a profit distribution plan, and mandates for share allotment and repurchase. Additionally, several directors were re-elected, and the board was authorized to fix directors’ remuneration. This successful AGM reflects strong shareholder support and positions the company for continued operational and strategic initiatives.
The most recent analyst rating on (HK:9969) stock is a Buy with a HK$11.76 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
InnoCare Pharma Ltd. announced that the National Medical Products Administration (NMPA) in China has approved Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. This approval marks the first CD19 antibody approved for this indication in China, potentially enhancing InnoCare’s market presence in the region. The approval is expected to have a significant impact on the company’s operations and industry positioning, given the high incidence of DLBCL in China, which accounts for 45.8% of all non-Hodgkin lymphoma cases in the country.
The most recent analyst rating on (HK:9969) stock is a Buy with a HK$11.76 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
InnoCare Pharma Limited has released its unaudited financial data for the first quarter of 2025, prepared according to Chinese accounting principles and the STAR Market requirements of the Shanghai Stock Exchange. The announcement advises shareholders and potential investors to exercise caution when dealing with the company’s securities, as the data has not been reviewed by independent auditors.
The most recent analyst rating on (HK:9969) stock is a Buy with a HK$11.76 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
InnoCare Pharma Ltd. has announced its upcoming annual general meeting scheduled for June 20, 2025, in Beijing, China. The meeting will address several key resolutions, including the approval of the 2024 financial statements, annual report, work report of the board of directors, and profit distribution plan. Additionally, the company seeks shareholder approval to authorize the directors to allot and issue new shares or securities convertible into shares, with limitations set by the Hong Kong Stock Exchange rules. This announcement could impact the company’s operational flexibility and shareholder value by potentially increasing the share capital.
InnoCare Pharma Limited has announced a board meeting scheduled for May 13, 2025, to review and approve the company’s unaudited first quarterly results for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market position and stakeholder interests.
InnoCare Pharma Ltd. has announced that its core product, Orelabrutinib, has received approval from the China National Medical Products Administration for the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This approval marks a significant expansion of Orelabrutinib’s indications, which previously included treatments for relapsed and refractory CLL/SLL, mantle cell lymphoma, and marginal zone lymphoma. The inclusion of Orelabrutinib in the Chinese Society of Clinical Oncology’s guidelines as a Class I recommended therapy further strengthens its market position and potential impact on a broader patient population.